Navigation Links
Sangamo BioSciences Announces Presentation At The Needham Healthcare Conference
Date:4/24/2013

RICHMOND, Calif., April 24, 2013 /PRNewswire/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced today that Edward Lanphier , Sangamo's president and CEO, will provide an update on the progress of Sangamo's ZFP Therapeutic® development programs and an overview of the company's business strategy at 12:50 pm ET on Wednesday, May 1, 2013, at the 12th Annual Needham Healthcare Conference which will be held in New York.

(Logo: http://photos.prnewswire.com/prnh/20130102/SF35903LOGO)

The presentation will be webcast live and may be accessed via a link on the Sangamo BioSciences website in the Investor Relations section under Events and Presentations. The presentation will be archived on the Sangamo website for two weeks after the event.

About Sangamo

Sangamo BioSciences, Inc. is focused on research and development of novel DNA-binding proteins for therapeutic gene regulation and genome editing. The Company has ongoing Phase 2 clinical trials to evaluate the safety and efficacy of a novel ZFP Therapeutic® for the treatment of HIV/AIDS. Sangamo's other therapeutic programs are focused on monogenic diseases, including hemophilia, Huntington's disease and  hemoglobinopathies such as beta-thalassemia and sickle cell anemia. Sangamo's core competencies enable the engineering of a class of DNA-binding proteins known as zinc finger DNA-binding proteins (ZFPs).  Engineering of ZFPs that recognize a specific DNA sequence enables the creation of sequence-specific ZFP Nucleases (ZFNs) for gene modification and ZFP transcription factors (ZFP TFs) that can control gene expression and, consequently, cell function. S
'/>"/>

SOURCE Sangamo BioSciences, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Sangamo BioSciences Announces Presentation At Regen Med Investor Day
2. Sangamo BioSciences Announces Fourth Quarter And Full Year 2012 Conference Call And Webcast
3. Sangamo BioSciences Announces Presentation At The Lazard Capital Markets Healthcare Conference
4. Sangamo BioSciences Announces Presentation At The Stifel Nicolaus 2012 Healthcare Conference
5. Sangamo BioSciences Announces Second Quarter 2012 Conference Call and Webcast
6. Sangamo BioSciences Announces Presentation at Seventh Annual JMP Securities Healthcare Conference
7. Sangamo BioSciences Announces Presentations At Upcoming Investor Conferences
8. Sangamo BioSciences Reports First Quarter 2012 Financial Results
9. Sangamo BioSciences Announces First Quarter 2012 Conference Call and Webcast
10. Sangamo BioSciences Announces Fourth Quarter and Full Year 2011 Conference Call and Webcast
11. Sangamo BioSciences Announces Presentation at J.P. Morgan Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... , Aug. 21, 2014  Decision Resources ... Brazil and Mexico ... uptake of several newly approved agents, the anticipated ... indication and the launch of emerging biologics will ... In particular, the emerging IL-5 inhibitors will introduce ...
(Date:8/21/2014)... , Aug. 21, 2014  China Cord Blood Corporation (NYSE: ... plan to release financial results for the first quarter ... after market close in the US.  ... a.m. ET on Friday, August 29, 2014 to discuss ... the Company,s recent developments, followed by a question and ...
(Date:8/21/2014)... Ontotext S4 , The Self Service Semantic ... Now the same enterprise hardened text mining, Linked Data ... is available to start-ups and mid-size businesses at a ... do not have resources to evaluate and prototype enterprise ... there is no need for on premise hardware provisioning ...
(Date:8/21/2014)... Wednesday of last week RENU 28, the world's first and ... for purchase in Australia and New Zealand, and the response ... is, if you think about the definition of aging, it's ... within your body. If you think about the definition of ... What RENU 28 does is it works with these tiny ...
Breaking Biology Technology:Asthma Agents Currently Face a Suboptimal Coverage Environment in Brazil and Mexico, and as the Treatment Armamentarium Expands, Competitiveness Will Further Intensify 2Asthma Agents Currently Face a Suboptimal Coverage Environment in Brazil and Mexico, and as the Treatment Armamentarium Expands, Competitiveness Will Further Intensify 3China Cord Blood Corporation to Report First Quarter of Fiscal 2015 Financial Results 2Ontotext Releases Text Mining & Semantic Technology Running in the Cloud – Welcome to “S4? 2Ontotext Releases Text Mining & Semantic Technology Running in the Cloud – Welcome to “S4? 3Ontotext Releases Text Mining & Semantic Technology Running in the Cloud – Welcome to “S4? 4RENU 28 Skin Care Now Available in Australia and New Zealand 2
... Biotech Product with ... Direct Consumer Benefits, DES MOINES, Iowa, ... oil trait from DuPont (NYSE: DD ),will deliver increased nutritional ... market. The high oleic soybean,oil trait is the next generation of ...
... Data presented at AAAAI 64th Annual Meeting also show ... effective treatment for HAE attacks across all body sites, ... a safe and effective therapy that rapidly relieves acute,abdominal ... a rare and serious genetic disorder, according to data,presented ...
... March 18 /PRNewswire/ - Aegera Therapeutics announced ... clinical trial for AEG33773, a,novel, orally bioavailable ... painful diabetic neuropathy. The Phase I study ... of AEG33773 using a randomized,double blind, placebo ...
Cached Biology Technology:Research Confirms Better Oil from New DuPont High Oleic Soybean Trait 2Research Confirms Better Oil from New DuPont High Oleic Soybean Trait 3C1-Esterase Inhibitor Concentrate Rapidly Relieves Abdominal and Facial Attacks in Patients with Hereditary Angioedema, According to Pivotal Study 2C1-Esterase Inhibitor Concentrate Rapidly Relieves Abdominal and Facial Attacks in Patients with Hereditary Angioedema, According to Pivotal Study 3C1-Esterase Inhibitor Concentrate Rapidly Relieves Abdominal and Facial Attacks in Patients with Hereditary Angioedema, According to Pivotal Study 4Aegera initiates Phase 1 clinical trial of AEG33773 - A small molecule in development for diabetic neuropathic pain 2
(Date:8/22/2014)... (Maximizing Access to Research Careers) Program has announced the ... & Practical Exercises Workshop which will be held on ... 25-26, 2014. These awards are meant to help ... underrepresented groups in the the FASEB Grant Writing Seminar ... 11 awards totaling $20,350. , The FASEB MARC Program ...
(Date:8/22/2014)... can probably remember the after-effects, including pain, swelling or ... back against the injury. When tissue in the body ... tissue regeneration. An inflammatory response acts as a protective ... to heal after injuries such as wounds and burns. ... situations in which foreign material is introduced, for example ...
(Date:8/22/2014)... important discoveries in basic and clinical research and ... into a complex offensive spanning multiple fronts. , ... lab could help find new and more selective ... that targets a specific enzyme overexpressed in certain ... from brain tumours. , Chemistry professor Christopher Cairo ...
Breaking Biology News(10 mins):Tissue regeneration using anti-inflammatory nanomolecules 2New enzyme targets for selective cancer therapies 2New enzyme targets for selective cancer therapies 3
... Using an extremely sensitive measurement technique, researchers at ... a lead-specific DNAzyme uses the lock and key reaction ... the same DNAzyme uses the induced fit reaction ... and key mechanism explains why this particular lead-specific DNAzyme ...
... Molecular Biology Laboratory [EMBL] announces Luxembourg as the ... EMBL,s council and ratified by the parliament of ... as the 20th member state. "EMBL is ... Franois Biltgen, Minister of Culture, Higher Education and ...
... researchers have engineered with a novel inkjet printing method ... harmful industrial solvents and explosives. Led by MIT ... to print thin sensor films onto a microchip, a ... highly sensitive gas detectors. Mass production would ...
Cached Biology News:The key to unlocking the secret of highly specific DNAzyme catalysis 2Luxembourg joins EMBL 2MIT's 'electronic nose' could detect hazards 2MIT's 'electronic nose' could detect hazards 3
Rabbit polyclonal to Retinoic Acid Receptor beta 2 ( Abpromise for all tested applications). entrezGeneID: 5915...
Ca2+ Channel Ca gamma 2 Purified Anti-Mouse, Anti-Rat, Anti-Human clone Polyclonal, Isotype Rabbit Ig, 50 µl Consult technical datasheet for details....
...
... for spontaneous ligand immobilization can be coupled with ... or receptor to create an affinity matrix of ... ligands via primary amines. Affi-Gel 10 gel couples ... to 11; Affi-Gel 15 gel couples acidic proteins ...
Biology Products: